khammond on DSKJM1Z7X2PROD with NOTICES

67942 Federal Register / Vol. 84, No. 239 / Thursday, December 12, 2019 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Final Effect of Designation of a Class 

of Employees for Addition to the 

Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice concerning 

the final effect of the HHS decision to 

designate a class of employees from the 

West Valley Demonstration Project in 

West Valley, New York, as an addition 

to the Special Exposure Cohort (SEC) 

under the Energy Employees 

Occupational Illness Compensation 

Program Act of 2000. 

FOR FURTHER INFORMATION CONTACT: 

Grady Calhoun, Director, Division of 

Compensation Analysis and Support, 

NIOSH, 1090 Tusculum Avenue, MS C– 

46, Cincinnati, OH 45226–1938, 

Telephone 513–533–6800. Information 

requests can also be submitted by email 

to DCAS@CDC.GOV. 

SUPPLEMENTARY INFORMATION: On 

October 25, 2019, as provided for under 

42 U.S.C. 7384l(14)(C), the Secretary of 

HHS designated the following class of 

employees as an addition to the SEC: 

All Atomic Weapons Employees who 

worked at the West Valley Demonstration 

Project in West Valley, New York, during the 

period from January 1, 1969, through 

December 31, 1973, for a number of work 

days aggregating at least 250 work days, 

occurring either solely under this 

employment or in combination with work 

days within the parameters established for 

one or more other classes of employees in the 

Special Exposure Cohort. 

This designation became effective on 

November 24, 2019. Therefore, 

beginning on November 24, 2019, 

members of this class of employees, 

defined as reported in this notice, 

became members of the SEC. 

Authority: 42 U.S.C. 7384q(b). 42 U.S.C. 

7384l(14)(C). 

John J. Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2019–26747 Filed 12–11–19; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–20–0020; Docket No. CDC–2019– 

0109] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period; 

Withdrawal. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) in the 

Department of Health and Human 

Services (HHS) announces the 

withdrawal of the notice published 

under the same title on December 6, 

2019 for public comment. 

DATES: December 12, 2019. 

FOR FURTHER INFORMATION CONTACT: 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: On 

December 6, 2019 CDC published a 

notice in the Federal Register titled 

‘‘Proposed Data Collection Submitted 

for Public Comment and 

Recommendations’’ (84 FR 66902). This 

notice with Federal Register Document 

2019–26370 and Docket number CDC– 

2019–0109, was published prematurely 

and inadvertently. The notice is being 

withdrawn immediately for public 

comment. A new notice will be 

published at a later date for public 

comment. 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2019–26692 Filed 12–11–19; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2016–E–2529] 

Determination of Regulatory Review 

Period for Purposes of Patent 

Extension; BRIVIACT ORAL 

SOLUTION, New Drug Application 

205838 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or the Agency) has 

determined the regulatory review period 

for BRIVIACT ORAL SOLUTION and is 

publishing this notice of that 

determination as required by law. FDA 

has made the determination because of 

the submission of an application to the 

Director of the U.S. Patent and 

Trademark Office (USPTO), Department 

of Commerce, for the extension of a 

patent which claims that human drug 

product. 

DATES: Anyone with knowledge that any 

of the dates as published (see the 

SUPPLEMENTARY INFORMATION section) are 

incorrect may submit either electronic 

or written comments and ask for a 

redetermination by February 10, 2020. 

Furthermore, any interested person may 

petition FDA for a determination 

regarding whether the applicant for 

extension acted with due diligence 

during the regulatory review period by 

June 9, 2020. See ‘‘Petitions’’ in the 

SUPPLEMENTARY INFORMATION section for 

more information. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before February 10, 

2020. The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of February 10, 2020. 

Comments received by mail/hand 

delivery/courier (for written/paper 

submissions) will be considered timely 

if they are postmarked or the delivery 

service acceptance receipt is on or 

before that date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal:

. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https:// 

tps://www.regulations.gov

w

ht

will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on 

ww.regulations.gov 

https://www.regulations.gov.